Introduction and Overview of DNA Repair Targets: From Bench to Clinic

DNA Repair in Cancer Therapy

Volumn , Issue , 2012, Pages 1-16

  Kelley, Mark R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873744743     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384999-1.10001-0     Document Type: Chapter

References (32)

1. Fredholm L. The discovery of the molecular structure of DNA - the double helix: A scientific breakthrough. Nobelprize.org March 2011, 29. http://nobelprize.org/educational/medicine/dna_double_helix/readmore.htm l.
2. Friedberg E.C. A brief history of the DNA repair field. Cell Res 2008, 18(1):3-7.
3. Kaelin W.G. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009, 1(10):99.
4. BERIS. Human Genome Project Information: Gene Therapy 2009. 11 June 2009 [cited 21 January 2011]. http://genomics.energy.gov/.
5. Hoeijmakers J.H. DNA damage, aging, and cancer. N Engl J Med 2009, 361(15):1475-1485.
6. Kelley M.R., Fishel M.L. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem 2008, 8(4):417-425.
7. Lazzaro F., Giannattasio M., Puddu F., Granata M., Pellicioli A., Plevani P., et al. Checkpoint mechanisms at the intersection between DNA damage and repair. DNA Repair (Amst) 2009, 8(9):1055-1067.
8. Underhill C., Toulmonde M., Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2010, 22(2):268-279.
9. Park C.K., Park S.H., Lee S.H., Kim C.Y., Kim D.W., Paek S.H., et al. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology 2009, 29(4):443-449.
10. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nature Rev 2004, 4(4):296-307.
11. Gordon M. Cancer chemotherapy: Drug classification and mechanism of action [cited 31 December 2010]. http://www.pharmacology2000.com/Anticancer/classes1.htm.
12. Connors T.A., Hare J.R. Proceedings: Mechanism of action of tumour inhibitory nitrosoureas. Br J Cancer 1975, 31(2):264.
13. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007, 6(8):1079-1099.
14. Park W.S., Ko E.A., Jung I.D., Son Y.K., Kim H.K., Kim N., et al. APE1/Ref-1 promotes the effect of angiotensin II on Ca2+ -activated K+ channel in human endothelial cells via suppression of NADPH oxidase. Arch Pharm Res 2008, 31(10):1291-1301.
15. Plummer R. Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target. Clin Cancer Res 2010, 16(18):4527-4531.
16. Rabik C.A., Njoku M.C., Dolan M.E. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 2006, 32(4):261-276.
17. Bapat A., Fishel M.L., Georgiadis M., Kelley M.R. Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 2009, 11(3):651-668.
18. Drew Y., Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol 2010, 22(1):67-71.
19. Lichtenberg J., Jacox E., Welch J.D., Kurz K., Liang X., Yang M.Q., et al. Word-based characterization of promoters involved in human DNA repair pathways. BMC Genomics 2009, 10(Suppl. 1):S18.
20. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
21. Cipak L., Jantova S. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy. Neoplasma 2010, 57(5):401-405.
22. Wicha M.S. Development of synthetic lethal strategies to target BRCA1-deficient breast cancer. Breast Cancer Res 2009, 11(5):108.
23. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7(12):2010-2019.
24. Tse A.N., Carvajal R., Schwartz G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007, 13(7):1955-1960.
25. Wesierska-Gadek J., Maurer M., Zulehner N., Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol 2011, 226(2):341-349.
26. Luo M., He H., Kelley M.R., Georgiadis M. Redox regulation of DNA repair: Implications for human health and cancer therapeutic development. Antioxid Redox Signal 2010, 12(11):1247-1269.
27. Hanawalt P.C. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002, 21(58):8949-8956.
28. Fleck O., Nielsen O. DNA repair. J Cell Sci 2004, 117(Pt 4):515-517.
29. Essers J., van Steeg H., de Wit J., Swagemakers S.M., Vermeij M., Hoeijmakers J.H., et al. Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J 2000, 19(7):1703-1710.
30. Astsaturov I., Ratushny V., Sukhanova A., Einarson M.B., Bagnyukova T., Zhou Y., et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010, 3(140). ra67.
31. Cancer Facts & Figures 2010 2010, American Cancer Society I, American Cancer Society, Inc., Atlanta.
32. Cancer Facts & Figures 2009 2009, American Cancer Society I, American Cancer Society, Inc., Atlanta.